Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer

References

• Tsimberidou A-M, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res Off J Am Assoc Cancer Res 2012; 18:6373-83; PMID:22966018; http://dx.doi.org/10.1158/1078-0432.CCR-12-1627
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, et al. USing multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311:1998-2006; PMID:24846037; http://dx.doi.org/10.1001/jama.2014.3741
   PubMed Web of Science ®Google Scholar
• Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, et al. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget 2014; 5(9):2349-54; PMID:24811890
   PubMed Web of Science ®Google Scholar
• Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, et al. Molecular tumor board: the university of California San Diego Moores Cancer experience. Oncologist 2014; 19(6):631-6; PMID:24797821; http://dx.doi.org/10.1634/theoncologist.2013-0405
   PubMed Web of Science ®Google Scholar
• Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 2014; theoncologist:2014-0011; PMID:24797823
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53; PMID:1905840; http://dx.doi.org/10.1126/science.1905840
   PubMed Web of Science ®Google Scholar
• cbioportal [Internet]. Available from: http://www.cbioportal.org/public-portal/index.do
   Google Scholar
• Baker L, Quinlan PR, Patten N, Ashfield A, Birse-Stewart-Bell L-J, McCowan C, Bourdon J-C, Purdie CA, Jordan LB, Dewar JA, et al. p53 mutation, deprivation and poor prognosis in primary breast cancer. Br J Cancer 2010; 102:719-26; PMID:20104224; http://dx.doi.org/10.1038/sj.bjc.6605540
   PubMed Web of Science ®Google Scholar
• Skaug V, Ryberg D, Arab EHKMO, Stangeland L, Myking AO, Haugen A. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 2000; 6:1031-7; PMID:10741731
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic Significance of p53 Alterations in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis. Clin Cancer Res 2000; 6:4055-63; PMID:11051256
   PubMed Web of Science ®Google Scholar
• Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 2012; 10:51; PMID:22642691; http://dx.doi.org/10.1186/1741-7015-10-51
   PubMed Web of Science ®Google Scholar
• Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014; 6:377-87; PMID:24440717; http://dx.doi.org/10.1016/j.celrep.2013.12.035
   PubMed Web of Science ®Google Scholar
• Sawai H, Yasuda A, Ochi N, Ma J, Matsuo Y, Wakasugi T, Takahashi H, Funahashi H, Sato M, Takeyama H. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol 2008; 8:56; PMID:19036165; http://dx.doi.org/10.1186/1471-230X-8-56
   PubMed Web of Science ®Google Scholar
• Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 2003; 10:203-8; PMID:12790783; http://dx.doi.org/10.1677/erc.0.0100203
   PubMed Web of Science ®Google Scholar
• Tang J-M, He Q-Y, Guo R-X, Chang X-J. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer Amst Neth 2006; 51:181-91; PMID:16324768; http://dx.doi.org/10.1016/j.lungcan.2005.10.003
   PubMed Web of Science ®Google Scholar
• Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She Q-B, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007; 104:7564-9; PMID:17452630; http://dx.doi.org/10.1073/pnas.0702507104
   PubMed Web of Science ®Google Scholar
• Chen M-L, Xu P-Z, Peng X, Chen WS, Guzman G, Yang X, Di Cristofano A, Pandolfi PP, Hay N. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/− mice. Genes Dev 2006; 20:1569-74; PMID:16778075; http://dx.doi.org/10.1101/gad.1395006
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9:550-62; PMID:19629070; http://dx.doi.org/10.1038/nrc2664
   PubMed Web of Science ®Google Scholar
• Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6:184-92; PMID:16453012; http://dx.doi.org/10.1038/nrc1819
   PubMed Web of Science ®Google Scholar
• Dillon LM, Miller TW. Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets 2014; 15:65-79; PMID:24387334; http://dx.doi.org/10.2174/1389450114666140106100909
   PubMed Web of Science ®Google Scholar
• Li L, Ross AH. Why is PTEN an important tumor suppressor? J Cell Biochem 2007; 102:1368-74; PMID:17972252; http://dx.doi.org/10.1002/jcb.21593
   PubMed Web of Science ®Google Scholar
• Fokas E, Prevo R, Hammond EM, Brunner TB, McKenna WG, Muschel RJ. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat Rev 2014; 40:109-17; PMID:23583268; http://dx.doi.org/10.1016/j.ctrv.2013.03.002
   PubMed Web of Science ®Google Scholar
• Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen J-H, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM. mTOR complex 2 is required for the development of prostate cancer induced by pten loss in Mice. Cancer Cell 2009; 15:148-59; PMID:19185849; http://dx.doi.org/10.1016/j.ccr.2008.12.017
   PubMed Web of Science ®Google Scholar
• Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008; 27:5477-85; PMID:18794882; http://dx.doi.org/10.1038/onc.2008.248
   PubMed Web of Science ®Google Scholar
• Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stål O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 2009; 69:4192-201; PMID:19435893; http://dx.doi.org/10.1158/0008-5472.CAN-09-0042
   PubMed Web of Science ®Google Scholar
• Takeda H, Takigawa N, Ohashi K, Minami D, Kataoka I, Ichihara E, Ochi N, Tanimoto M, Kiura K. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res 2013; 319:417-23; PMID:23274758; http://dx.doi.org/10.1016/j.yexcr.2012.12.018
   PubMed Web of Science ®Google Scholar
• Holsinger FC, Piha-Paul SA, Janku F, Hong DS, Atkins JT, Tsimberidou AM, Kurzrock R. Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol Off J Am Soc Clin Oncol 2013; 31:e137-40; PMID:23358976; http://dx.doi.org/10.1200/JCO.2012.43.2716
   PubMed Web of Science ®Google Scholar
• Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011; 10:558-65; PMID:21216929; http://dx.doi.org/10.1158/1535-7163.MCT-10-0994
   PubMed Web of Science ®Google Scholar
• Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol Off J Am Soc Clin Oncol 2012; 30:777-82; PMID:22271473; http://dx.doi.org/10.1200/JCO.2011.36.1196
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010; 120:2858-66; PMID:20664172; http://dx.doi.org/10.1172/JCI37539
   PubMed Web of Science ®Google Scholar
• Alhejaily A, Day AG, Feilotter HE, Baetz T, Lebrun DP. Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome. Clin Cancer Res Off J Am Assoc Cancer Res 2014; 20:1676-86; PMID:24449825; http://dx.doi.org/10.1158/1078-0432.CCR-13-2175
   PubMed Web of Science ®Google Scholar
• Xing X, Cai W, Shi H, Wang Y, Li M, Jiao J, Chen M. The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis. Br J Cancer 2013; 108:2542-8; PMID:23703248; http://dx.doi.org/10.1038/bjc.2013.251
   PubMed Web of Science ®Google Scholar
• Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, et al. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 2013; 4:705-14; PMID:23670029
   PubMed Web of Science ®Google Scholar
• Pappano WN, Zhang Q, Tucker LA, Tse C, Wang J. Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells. BMC Cancer 2014; 14:430; PMID:24927813; http://dx.doi.org/10.1186/1471-2407-14-430
   PubMed Web of Science ®Google Scholar
• Levy N, Yonish-Rouach E, Oren M, Kimchi A. Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression. Mol Cell Biol 1993; 13:7942-52; PMID:8247009
   PubMed Web of Science ®Google Scholar
• Lesko AC, Goss KH, Prosperi JR. Exploiting APC function as a novel cancer therapy. Curr Drug Targets 2014; 15:90-102; PMID:24200292; http://dx.doi.org/10.2174/1389450114666131108155418
   PubMed Web of Science ®Google Scholar
• Palacio-Rúa KA, Isaza-Jiménez LF, Ahumada-Rodríguez E, Muñetón-Peña CM. [Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer]. Rev Gastroenterol Mex 2014; 79(2):79-89; PMID:24861525; http://dx.doi.org/10.1016/j.rgmx.2014.05.001
   PubMedGoogle Scholar
• Von Hoff DD, Stephenson JJ, Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol Off J Am Soc Clin Oncol 2010; 28:4877-83; PMID:20921468; http://dx.doi.org/10.1200/JCO.2009.26.5983
   PubMed Web of Science ®Google Scholar
• Janku F, Berry DA, Gong J, Parsons HA, Stewart DJ, Kurzrock R. Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clin Cancer Res Off J Am Assoc Cancer Res 2012; 18:6356-63; PMID:23014530; http://dx.doi.org/10.1158/1078-0432.CCR-12-0178
   PubMed Web of Science ®Google Scholar
• Rich JT, Neely JG, Paniello RC, Voelker CCJ, Nussenbaum B, Wang EW. A practical guide to understanding Kaplan-Meier curves. Otolaryngol–Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg 2010; 143:331-6; PMID:20723767; http://dx.doi.org/10.1016/j.otohns.2010.05.007
   PubMed Web of Science ®Google Scholar
• Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res 2010; 1:274-8; PMID:21455458; http://dx.doi.org/10.4103/0974-7788.76794
   PubMedGoogle Scholar
• Bewick V, Cheek L, Ball J. Statistics review 14: logistic regression. Crit Care 2005; 9:112-8; PMID:15693993; http://dx.doi.org/10.1186/cc3045
   PubMed Web of Science ®Google Scholar